Publication | Open Access

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

UrologyGenitourinary CancerMedicinePharmacologyCabozantinib Versus SunitinibCheckmate 9ErFirst-line TreatmentPharmacotherapyAnti-cancer AgentImmune Checkpoint InhibitorCancer TreatmentOncologyMolecular Oncology